https://www.jnj.com/rss-feed/all.rss RSS feed all en-US Sat, 07 Nov 2026 15:14:42 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-phase-2-nipocalimab-study-data-in-sjogrens-disease-that-reveal-insights-on-importance-of-symptom-improvements-most-valued-by-patients · New patient experience dataa to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain · Patient insights complement Phase 2 study results demonstrating a 50% increase in saliva productionb in more than twice as many patients on nipocalimab compared to placeboc · Two Phase 3 studies are ongoing, evaluating nipocalimab in Sjögren’s disease including these measures critical to patients Sat, 07 Nov 2026 15:14:42 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-phase-2-nipocalimab-study-data-in-sjogrens-disease-that-reveal-insights-on-importance-of-symptom-improvements-most-valued-by-patients https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-icotyde-icotrokinra-delivers-significant-improvement-in-psoriatic-arthritis-disease-activity-among-biologic-naive-patients-with-once-daily-targeted-oral-peptide · Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 · ICOTYDE is a first-in-class IL-23R targeted oral peptide, demonstrating significant joint and skin improvements and a favorable safety profile in a once-daily pill Sat, 07 Nov 2026 15:11:22 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-icotyde-icotrokinra-delivers-significant-improvement-in-psoriatic-arthritis-disease-activity-among-biologic-naive-patients-with-once-daily-targeted-oral-peptide https://www.jnj.com/media-center/press-releases/new-icotyde-icotrokinra-data-reinforces-first-line-systemic-use-in-plaque-psoriasis-with-powerful-skin-clearance-and-consistent-safety-profile · ICOTYDE met both co-primary endpoints, with 70% of adults and adolescents with moderate-to-severe plaque psoriasis achieving clear or almost clear skin (IGA 0/1) and 55% achieving PASI 90 at Week 16 · Results showed ICOTYDE achieved non-inferiority to ustekinumab, with numerically higher skin clearance rates across all patient types · ICOTYDE delivered a 17-point improvement in complete skin clearance versus ustekinumab in systemic-naïve patients at Week 28 (48% versus 31%) Fri, 06 Nov 2026 13:00:16 GMT https://www.jnj.com/media-center/press-releases/new-icotyde-icotrokinra-data-reinforces-first-line-systemic-use-in-plaque-psoriasis-with-powerful-skin-clearance-and-consistent-safety-profile https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-u-s-fda-approval-of-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-as-first-and-only-dual-targeted-therapy-for-advanced-head-and-neck-cancer · Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1 · First advancement in the second-line treatment setting for recurrent or metastatic head and neck cancer in a decade, bringing a new subcutaneous option to patients with significant unmet need 2-3 · Extending its well-established, dual-targeted benefit beyond lung cancer, RYBREVANT FASPRO™ targets both EGFR and MET pathways – two key drivers of tumor progression in head and neck cancer 2 Thu, 05 Nov 2026 22:59:32 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-u-s-fda-approval-of-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-as-first-and-only-dual-targeted-therapy-for-advanced-head-and-neck-cancer https://www.jnj.com/media-center/press-releases/johnson-johnsons-novel-shockwave-javelin-coronary-ivl-catheter-delivers-positive-results-in-pivotal-forward-cad-ide-study 30-day data from the FORWARD CAD IDE study demonstrate favorable safety and efficacy outcomes for the Shockwave Javelin Coronary Intravascular Lithotripsy (IVL) catheter when used to modify highly stenosed, challenging calcific coronary lesions Sun, 01 Nov 2026 21:30:12 GMT https://www.jnj.com/media-center/press-releases/johnson-johnsons-novel-shockwave-javelin-coronary-ivl-catheter-delivers-positive-results-in-pivotal-forward-cad-ide-study https://www.jnj.com/media-center/press-releases/data-show-positive-survival-and-patient-outcomes-with-best-practice-impella-support-in-hrpci-in-contrast-to-chip-bcis3-study-results Analyses presented at TCT highlight how patient selection, timely Impella support and consistent care protocols may help improve outcomes during and after complex heart procedures Sun, 01 Nov 2026 13:00:23 GMT https://www.jnj.com/media-center/press-releases/data-show-positive-survival-and-patient-outcomes-with-best-practice-impella-support-in-hrpci-in-contrast-to-chip-bcis3-study-results https://www.jnj.com/media-center/press-releases/record-26-abstracts-at-tct-2026-adds-to-more-than-20-years-of-data-demonstrating-the-safety-efficacy-and-cost-effectiveness-of-impella-heart-pumps Thu, 29 Oct 2026 13:13:47 GMT https://www.jnj.com/media-center/press-releases/record-26-abstracts-at-tct-2026-adds-to-more-than-20-years-of-data-demonstrating-the-safety-efficacy-and-cost-effectiveness-of-impella-heart-pumps https://www.jnj.com/media-center/press-releases/johnson-johnson-to-host-enterprise-business-review/2026 Tue, 27 Oct 2026 11:30:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-host-enterprise-business-review/2026 https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-combination-demonstrates-77-overall-response-rate-in-first-line-treatment-of-patients-with-advanced-head-and-neck-cancer Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study Data highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth and resistance seen in 80 to 90 percent of HNSCC Sun, 25 Oct 2026 18:22:46 GMT https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-combination-demonstrates-77-overall-response-rate-in-first-line-treatment-of-patients-with-advanced-head-and-neck-cancer https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-75-tumor-response-rate-in-advanced-prostate-cancer-with-jnj-6143-a-first-in-class-riptac-molecule JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed tumor-selective protein in prostate cancer cells Among patients with measurable disease in the 50 mg cohort, 75% achieved a complete or partial tumor response in the Phase 1 study 77% of patients achieved a confirmed PSA reduction of at least 50%, including nearly half whose PSA levels fell by at least 90% Sun, 25 Oct 2026 11:08:17 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-75-tumor-response-rate-in-advanced-prostate-cancer-with-jnj-6143-a-first-in-class-riptac-molecule https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-erleada-apalutamide-treatment-before-and-after-surgery-reduces-risk-of-recurrence-or-death-by-62-versus-surgery-alone-in-high-risk-prostate-cancer · New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery · Twice as many patients remained free from subsequent treatment at three years with perioperative apalutamide plus ADT compared with surgery alone · Results evaluated outcomes versus surgery alone, building on the primary results presented at ASCO 2026 Sat, 24 Oct 2026 13:23:54 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-erleada-apalutamide-treatment-before-and-after-surgery-reduces-risk-of-recurrence-or-death-by-62-versus-surgery-alone-in-high-risk-prostate-cancer https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-the-next-generation-of-solid-tumor-therapies-with-new-data-at-esmo-2026 · First readout following acquisition of the RIPTAC™ platform shows promising anti-tumor activity with JNJ-6143, a novel oral investigational molecule, in difficult-to-treat prostate cancer · New first-line head and neck cancer data highlight the potential of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) and its dual EGFR-MET approach, building on the established role of RYBREVANT®-based regimens in lung cancer · New ERLEADA® (apalutamide) substudy findings in prostate cancer build on the primary results presented at ASCO 2026 Fri, 23 Oct 2026 12:30:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-the-next-generation-of-solid-tumor-therapies-with-new-data-at-esmo-2026 https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-breadth-of-rheumatology-innovation-at-acr-convergence-2026-with-43-presentations-including-late-breaking-data-on-icotyde-icotrokinra-in-psoriatic-arthritis Patient data from the Phase 2 study of nipocalimab in Sjögren’s disease identify improvements in most core patient-relevant symptoms, with associated improvements in health-related quality of life Positive Phase 2 data support continued development of nipocalimab in systemic lupus erythematosus; Phase 3 study is recruiting Thu, 22 Oct 2026 12:05:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-breadth-of-rheumatology-innovation-at-acr-convergence-2026-with-43-presentations-including-late-breaking-data-on-icotyde-icotrokinra-in-psoriatic-arthritis https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-first-real-world-varipulse-pro-platform-data-and-12-month-omnypulse-platform-outcomes-for-atrial-fibrillation-treatment-at-aphrs-2026 VARIPURE findings reported 100% acute procedural success with the VARIPULSE Pro Platform, 0.4% primary adverse event rate and a mean ablation time of 17.9 minutesi Omny-IRE data showed 82.5% of patients treated with the investigational OMNYPULSE Platform1remained free from documented atrial arrhythmia recurrence at 12 months under stringent monitoringii Thu, 22 Oct 2026 11:46:53 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-first-real-world-varipulse-pro-platform-data-and-12-month-omnypulse-platform-outcomes-for-atrial-fibrillation-treatment-at-aphrs-2026 https://www.jnj.com/media-center/press-releases/johnson-johnson-to-showcase-the-future-of-surgical-intelligence-at-abu-dhabi-future-health-summit-2026 · Company to showcase MONARCH™ robotics platform and Polyphonic™ digital ecosystem · New ecosystem collaboration announced at the event will support the future of surgical intelligence Tue, 20 Oct 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-showcase-the-future-of-surgical-intelligence-at-abu-dhabi-future-health-summit-2026 https://www.jnj.com/media-center/press-releases/johnson-johnson-launches-next-generation-shockwave-c2-aero-fly-coronary-ivl-catheter-cutting-ivl-treatment-time-in-half · Next-generation intravascular lithotripsy (IVL) catheter delivers pulses at 2 Hz, improving efficiency in calcium modification treatment of coronary artery disease1 · Faster pulsing reduces duration patients may experience procedure-induced ischemic time2 · Shockwave C2 Aero Fly builds on the best-in-class features of Shockwave C2 Aero, featuring leading deliverability, crossability and repositioning capabilities3 Tue, 20 Oct 2026 11:45:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-launches-next-generation-shockwave-c2-aero-fly-coronary-ivl-catheter-cutting-ivl-treatment-time-in-half https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-data-showing-tremfya-guselkumab-is-the-only-il-23-to-deliver-durable-fistula-remission-through-48-weeks-in-crohns-disease-with-perianal-fistula · TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group · These findings build on the Phase 3 clinical program, demonstrating efficacy in a dedicated, randomized, placebo-controlled trial in patients with this debilitating and challenging manifestation of Crohn’s disease Mon, 19 Oct 2026 12:01:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-data-showing-tremfya-guselkumab-is-the-only-il-23-to-deliver-durable-fistula-remission-through-48-weeks-in-crohns-disease-with-perianal-fistula https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treatment-of-relapsed-refractory-multiple-myeloma · If approved, TALVEY® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple myeloma as early as second line · CHMP recommendation based on Phase 3 results where talquetamab and daratumumab, with or without pomalidomide, showed progression-free survival of up to 81% and overall survival of up to 89% at 24 months1 Fri, 16 Oct 2026 12:55:21 GMT https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treatment-of-relapsed-refractory-multiple-myeloma https://www.jnj.com/media-center/press-releases/new-tremfya-guselkumab-study-shows-consistent-perianal-fistula-remission-across-key-crohns-disease-patient-subgroups · New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure · Findings build on first positive results where TREMFYA achieved combined fistula remission rates of up to 28% across dosing groups · Results come from the first dedicated Phase 3 randomized, placebo-controlled trial in adults managing Crohn’s disease with perianal fistula in more than 20 years Tue, 13 Oct 2026 20:10:51 GMT https://www.jnj.com/media-center/press-releases/new-tremfya-guselkumab-study-shows-consistent-perianal-fistula-remission-across-key-crohns-disease-patient-subgroups https://www.jnj.com/media-center/press-releases/tremfya-guselkumab-demonstrated-sustained-clinical-and-endoscopic-remission-through-3-years-in-moderately-to-severely-active-crohns-disease · New long-term data showed clinical remission rates of up to 94% and endoscopic remission rates of up to 61% in adults with moderately to severely active Crohn’s disease · 88% of patients achieved 90-day corticosteroid-free clinical remission Tue, 13 Oct 2026 20:09:44 GMT https://www.jnj.com/media-center/press-releases/tremfya-guselkumab-demonstrated-sustained-clinical-and-endoscopic-remission-through-3-years-in-moderately-to-severely-active-crohns-disease https://www.jnj.com/media-center/press-releases/johnson-johnson-q3-2026-earnings-ceo-and-cfo-prepared-remarks On the Q3 2026 earnings call, Johnson & Johnson Chairman and CEO Joaquin Duato and Executive Vice President and CFO Joe Wolk discussed recent performance and long-term outlook. Tue, 13 Oct 2026 13:07:42 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-q3-2026-earnings-ceo-and-cfo-prepared-remarks https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2026 Tue, 13 Oct 2026 10:25:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2026 https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q3-2026-results-raises-2026-guidance 2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* • Tue, 13 Oct 2026 10:20:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q3-2026-results-raises-2026-guidance https://www.jnj.com/media-center/press-releases/new-johnson-johnson-icotyde-icotrokinra-long-term-data-demonstrate-robust-2-year-results-in-the-treatment-of-adults-and-adolescents-with-plaque-psoriasis · Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a continued favorable safety profile Fri, 09 Oct 2026 11:01:23 GMT https://www.jnj.com/media-center/press-releases/new-johnson-johnson-icotyde-icotrokinra-long-term-data-demonstrate-robust-2-year-results-in-the-treatment-of-adults-and-adolescents-with-plaque-psoriasis https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-icotyde-icotrokinra-data-in-difficult-to-treat-plaque-psoriasis-with-proven-durability-through-2-years-affirming-its-use-as-a-powerful-first-line-systemic-therapy • Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body • 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112 Fri, 02 Oct 2026 10:12:35 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-icotyde-icotrokinra-data-in-difficult-to-treat-plaque-psoriasis-with-proven-durability-through-2-years-affirming-its-use-as-a-powerful-first-line-systemic-therapy